# Axsome Therapeutics (AXSM) — Earnings

AXSM · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/axsm/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.99 |
| EPS estimate | −$0.89 |
| EPS surprise | −10.97% |
| Revenue surprise | −2.15% |
| Revenue | $216.4M |
| Revenue estimate | $221.1M |
| Reported | Aug 10, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1579428/000119312526342360/axsm-20260630.htm) |

Axsome Therapeutics reported Q2 2026 results on August 10, 2026. It posted a loss of $0.99 per share, wider than the expected loss of $0.89, a miss of 10.97%. Revenue was $216.4 million, slightly below the $221.1 million estimate. Compared with Q2 2025, revenue rose about 44% from $150.0 million, while the loss per share was close to the year-earlier $0.97.

Every quarter in the table, back to Q3 2021, was a loss. The annual loss per share was $4.57 in 2022, $5.20 in 2023 and $5.99 in 2024, then narrowed to $3.69 in 2025. The first half of 2026 adds up to a loss of $2.25. Revenue has grown from $8.8 million in Q2 2022 to the latest $216.4 million, the highest in the table. Annual revenue rose from $270.6 million in 2023 to $384.7 million in 2024 and $637.2 million in 2025. Axsome beat the EPS estimate in seven of the last 20 quarters and missed in 13.

Axsome reported Q3 between November 3 and November 12 in each of the past five years. That points to early or mid-November 2026 for the next report. It will show whether revenue keeps rising and how the loss compares.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 10, 2026 | −$0.89 | −$0.99 | -10.97% | $221.1M | $216.4M |
| Q1 2026 | May 4, 2026 | −$0.81 | −$1.26 | -54.70% | $191.2M | $189.4M |
| Q4 2025 | Feb 23, 2026 | −$0.69 | −$0.56 | 19.13% | $194.6M | $194.7M |
| Q3 2025 | Nov 3, 2025 | −$0.86 | −$0.94 | -9.15% | $162.7M | $171.0M |
| Q2 2025 | Aug 4, 2025 | −$1.06 | −$0.97 | 8.07% | $138.0M | $150.0M |
| Q1 2025 | May 5, 2025 | −$1.35 | −$1.22 | 9.71% | $119.2M | $121.5M |
| Q4 2024 | Feb 18, 2025 | −$1.00 | −$1.54 | -53.85% | $118.1M | $118.8M |
| Q3 2024 | Nov 12, 2024 | −$1.38 | −$1.34 | 3.14% | $98.4M | $103.7M |
| Q2 2024 | Aug 5, 2024 | −$1.31 | −$1.67 | -27.76% | $86.9M | $87.2M |
| Q1 2024 | May 6, 2024 | −$1.20 | −$1.44 | -19.55% | $73.3M | $75.0M |
| Q4 2023 | Feb 20, 2024 | −$1.17 | −$2.08 | -77.57% | $69.2M | $71.5M |
| Q3 2023 | Nov 6, 2023 | −$1.20 | −$1.32 | -9.70% | $54.9M | $57.8M |
| Q2 2023 | Aug 7, 2023 | −$1.21 | −$1.54 | -26.91% | $40.9M | $46.7M |
| Q1 2023 | May 8, 2023 | −$1.30 | −$0.26 | 80.06% | $25.5M | $94.6M |
| Q4 2022 | Feb 27, 2023 | −$1.13 | −$1.41 | -25.23% | $21.8M | $24.4M |
| Q3 2022 | Nov 7, 2022 | −$1.05 | −$1.07 | -1.90% | $16.6M | $16.8M |
| Q2 2022 | Aug 9, 2022 | −$1.01 | −$1.06 | -5.36% | $6.9M | $8.8M |
| Q1 2022 | May 2, 2022 | −$1.00 | −$1.03 | -2.72% | — | — |
| Q4 2021 | Mar 1, 2022 | −$1.02 | −$0.90 | 11.89% | — | — |
| Q3 2021 | Nov 8, 2021 | −$0.95 | −$0.93 | 2.50% | — | — |

## Frequently Asked Questions

### When did Axsome Therapeutics (AXSM) last report earnings?

Axsome Therapeutics last reported on Aug 10, 2026, covering fiscal Q2 2026.

### Did AXSM beat earnings estimates?

No. Axsome Therapeutics reported EPS of −$0.99 for Q2 2026 against a −$0.89 estimate — a 10.97% miss.

### How much revenue did AXSM report last quarter?

Axsome Therapeutics reported $216.4M in revenue for Q2 2026, against a consensus estimate of $221.1M.

## Similar Stocks

- [JAZZ](https://www.lighthorse.io/tickers/jazz) — Jazz Pharmaceuticals plc - Ordinary Shares

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).